425 related articles for article (PubMed ID: 21194787)
1. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Saftig P; Reiss K
Eur J Cell Biol; 2011; 90(6-7):527-35. PubMed ID: 21194787
[TBL] [Abstract][Full Text] [Related]
2. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
[TBL] [Abstract][Full Text] [Related]
3. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
4. Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.
Mezyk-Kopeć R; Bzowska M; Stalińska K; Chełmicki T; Podkalicki M; Jucha J; Kowalczyk K; Mak P; Bereta J
Cytokine; 2009 Jun; 46(3):309-15. PubMed ID: 19346138
[TBL] [Abstract][Full Text] [Related]
5. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
Pruessmeyer J; Ludwig A
Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
[TBL] [Abstract][Full Text] [Related]
6. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
[TBL] [Abstract][Full Text] [Related]
7. ADAM10 is the major sheddase responsible for the release of membrane-associated meprin A.
Herzog C; Haun RS; Ludwig A; Shah SV; Kaushal GP
J Biol Chem; 2014 May; 289(19):13308-22. PubMed ID: 24662289
[TBL] [Abstract][Full Text] [Related]
8. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
9. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein.
Taylor DR; Parkin ET; Cocklin SL; Ault JR; Ashcroft AE; Turner AJ; Hooper NM
J Biol Chem; 2009 Aug; 284(34):22590-600. PubMed ID: 19564338
[TBL] [Abstract][Full Text] [Related]
10. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Ebsen H; Schröder A; Kabelitz D; Janssen O
PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
[TBL] [Abstract][Full Text] [Related]
11. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases.
Bender M; Hofmann S; Stegner D; Chalaris A; Bösl M; Braun A; Scheller J; Rose-John S; Nieswandt B
Blood; 2010 Oct; 116(17):3347-55. PubMed ID: 20644114
[TBL] [Abstract][Full Text] [Related]
12. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
[TBL] [Abstract][Full Text] [Related]
13. The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.
Zheng Y; Verhoeff TA; Perez Pardo P; Garssen J; Kraneveld AD
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374371
[TBL] [Abstract][Full Text] [Related]
14. Human and Murine Interleukin 23 Receptors Are Novel Substrates for A Disintegrin and Metalloproteases ADAM10 and ADAM17.
Franke M; Schröder J; Monhasery N; Ackfeld T; Hummel TM; Rabe B; Garbers C; Becker-Pauly C; Floss DM; Scheller J
J Biol Chem; 2016 May; 291(20):10551-61. PubMed ID: 26961870
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.
Minond D; Cudic M; Bionda N; Giulianotti M; Maida L; Houghten RA; Fields GB
J Biol Chem; 2012 Oct; 287(43):36473-87. PubMed ID: 22927435
[TBL] [Abstract][Full Text] [Related]
16. Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases.
Hiraoka Y; Yoshida K; Ohno M; Matsuoka T; Kita T; Nishi E
Biochem Biophys Res Commun; 2008 May; 370(1):154-8. PubMed ID: 18355445
[TBL] [Abstract][Full Text] [Related]
17. Ectodomain shedding of Fcalpha receptor is mediated by ADAM10 and ADAM17.
Peng M; Guo S; Yin N; Xue J; Shen L; Zhao Q; Zhang W
Immunology; 2010 May; 130(1):83-91. PubMed ID: 20059578
[TBL] [Abstract][Full Text] [Related]
18. The Antiatherogenic Effect of Fish Oil in Male Mice Is Associated with a Diminished Release of Endothelial ADAM17 and ADAM10 Substrates.
Speck N; Brandsch C; Schmidt N; Yazdekhasti N; Hirche F; Lucius R; Rimbach G; Stangl GI; Reiss K
J Nutr; 2015 Jun; 145(6):1218-26. PubMed ID: 25926412
[TBL] [Abstract][Full Text] [Related]
19. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
Araya HF; Sepulveda H; Lizama CO; Vega OA; Jerez S; Briceño PF; Thaler R; Riester SM; Antonelli M; Salazar-Onfray F; Rodríguez JP; Moreno RD; Montecino M; Charbonneau M; Dubois CM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2018 Nov; 119(10):8204-8219. PubMed ID: 29923217
[TBL] [Abstract][Full Text] [Related]
20. ADAM10 and ADAM17 have opposite roles during sprouting angiogenesis.
Caolo V; Swennen G; Chalaris A; Wagenaar A; Verbruggen S; Rose-John S; Molin DG; Vooijs M; Post MJ
Angiogenesis; 2015 Jan; 18(1):13-22. PubMed ID: 25218057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
